Literature DB >> 30467792

The experience of providing hospice care concurrent with cancer treatment in the VA.

Leah M Haverhals1,2, Chelsea E Manheim3, Vincent Mor4,5, Mary Ersek6,7,8, Bruce Kinosian6,9, Karl A Lorenz10,11, Katherine E Faricy-Anderson4,12, Risha A Gidwani-Marszowski10,11,13, Cari Levy3,14.   

Abstract

PURPOSE: Veterans with advanced cancer can receive hospice care concurrently with treatments such as radiation and chemotherapy. However, variations exist in concurrent care use across Veterans Affairs (VA) medical centers (VAMCs), and overall, concurrent care use is relatively rare. In this qualitative study, we aimed to identify, describe, and explain factors that influence the provision of concurrent cancer care (defined as chemotherapy or radiation treatments provided with hospice) for veterans with terminal cancer.
METHODS: From August 2015 to April 2016, we conducted six site visits and interviewed 76 clinicians and staff at six VA sites and their contracted community hospices, including community hospices (n = 16); VA oncology (n = 25); VA palliative care (n = 17); and VA inpatient hospice and palliative care units (n = 18).
RESULTS: Thematic qualitative content analysis found three themes that influenced the provision of concurrent care: (1) clinicians and staff at community hospices and at VAs viewed concurrent care as a viable care option, as it preserved hope and relationships while patient goals are clarified during transitions to hospice; and (2) the presence of dedicated liaisons facilitated care coordination and education about concurrent care; however, (3) clinicians and staff concerns about Medicare guideline compliance hindered use of concurrent care.
CONCLUSIONS: While concurrent care is used by a small number of veterans with advanced cancer, VA staff valued having the option available and as a bridge to hospice. Hospice staff felt concurrent care improved care coordination with VAMCs, but use may be tempered due to concerns related to Medicare compliance.

Entities:  

Keywords:  Cancer; Concurrent care; Hospice; Palliative care; Veterans

Mesh:

Year:  2018        PMID: 30467792      PMCID: PMC6391175          DOI: 10.1007/s00520-018-4552-z

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  6 in total

1.  Thematic Analysis of Hospice Mentions in the Health Records of Veterans with Advanced Kidney Disease.

Authors:  Ann M O'Hare; Catherine R Butler; Janelle S Taylor; Susan P Y Wong; Elizabeth K Vig; Ryan S Laundry; Melissa W Wachterman; Paul L Hebert; Chuan-Fen Liu; Nilka Rios-Burrows; Claire A Richards
Journal:  J Am Soc Nephrol       Date:  2020-08-06       Impact factor: 10.121

2.  Concurrent Hospice Care and Cancer-Directed Treatment for Advanced Lung Cancer and Receipt of Aggressive Care at the End of Life in the Veteran's Health Administration.

Authors:  Carolyn J Presley; Ling Han; John R O'Leary; Weiwei Zhu; Emily Corneau; Herta Chao; Tracy Shamas; Michal Rose; Karl Lorenz; Cari R Levy; Vincent Mor; Cary P Gross
Journal:  J Palliat Med       Date:  2020-03-02       Impact factor: 2.947

3.  Inpatient Hospices in Germany: Medical Care Situation and Use of Supportive Oncological Therapies for Symptom Control in Tumor Patients.

Authors:  Ulrich Kaiser; Ursula Vehling-Kaiser; Ana Hoffmann; Florian Kaiser
Journal:  Palliat Med Rep       Date:  2022-08-18

Review 4.  Pediatric Concurrent Hospice Care: A Scoping Review and Directions for Future Nursing Research.

Authors:  Lisa C Lindley; Jessica Keim-Malpass; Radion Svynarenko; Melanie J Cozad; Jennifer W Mack; Pamela S Hinds
Journal:  J Hosp Palliat Nurs       Date:  2020-06       Impact factor: 2.131

5.  Forced to Choose: When Medicare Policy Disrupts End-of-Life Care.

Authors:  Joan G Carpenter
Journal:  J Aging Soc Policy       Date:  2020-03-29

6.  Use of symptom-focused oncological cancer therapies in hospices: a retrospective analysis.

Authors:  Ulrich Kaiser; Ursula Vehling-Kaiser; Fabian Kück; Nicolae-Catalin Mechie; Ana Hoffmann; Florian Kaiser
Journal:  BMC Palliat Care       Date:  2020-09-12       Impact factor: 3.234

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.